pegvisomant: Clinical Trials

3 trials of pegvisomant, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 terminated. 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 13Completed 2, Terminated 1

Follow pegvisomant: new trials by email Literature Review of pegvisomant trials Research Report on pegvisomant

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Relative Bioavailability Study To Evaluate Safety, Tolerability And Pharmacokinetic Comparability Of Pegvisomant 1 X 30 Mg Vs 2 X 15 Mg Subcutaneously Administered In Healthy Subjects
1 x 30 mg/mL pegvisomant, 2 x 15 mg/mL pegvisomant - Healthy Volunteers
Phase 1CompletedPfizer172013-08-012013-12-12
Safety, Tolerability and Relative Bioavailability of Pegvisomant in Healthy Subjects
pegvisomant - Bioavailability
Phase 1CompletedPfizer142010-10-012012-01-05
Figitumumab Combined With Pegvisomant For Advanced Solid Tumors
figitumumab, pegvisomant - Colorectal Neoplasms, Lung Neoplasms
Phase 1TerminatedPfizer242009-11-012013-12-13

Conditions studied

Breast Neoplasms (1)  ·  Colorectal Neoplasms (1)  ·  Lung Neoplasms (1)  ·  Prostatic Neoplasms (1)  ·  Sarcoma (1)

Sponsors

Pfizer (3)

Countries

Belgium (1)  ·  Canada (1)  ·  Finland (1)  ·  Germany (1)  ·  Singapore (1)  ·  United States (1)